Nanoxis AB

Nanoxis is a biotechnology company with extensive knowledge and experience in membrane protein research. Based on our unique LPI™ technology we offer products and services to membrane protein researchers worldwide. Roughly 70% percent of all major drugs sold today target membrane proteins linked to diseases such as diabetes, hypertension, asthma, cancer, obesity, schizophrenia, Parkinson�s, depression and epilepsy. For two thirds of all anticipated new drugs it has been predicted that they will need to act on membrane proteins.